Editorial Commentary
Real-world study: from real-world data to real-world evidence
Translational Breast Cancer Research
2020;
1:
21
(30 July 2020)
Case Report
Analysis of tumor heterogeneity at the molecular level: a case report of efficacy separation in metastatic breast cancer
Translational Breast Cancer Research
2020;
1:
20
(30 July 2020)
Case Report
An advanced refractory breast cancer patient with human epidermal growth factor receptor 2 discordance: a case report
Translational Breast Cancer Research
2020;
1:
19
(30 July 2020)
Review Article
Practice of surgical treatment of breast cancer in china during the novel coronavirus COVID-19 outbreak
Translational Breast Cancer Research
2020;
1:
18
(30 July 2020)
Review Article
The essence of real-world study in cancer research
Translational Breast Cancer Research
2020;
1:
17
(30 July 2020)
Original Article
Neoadjuvant chemotherapy versus surgery as the initial option for T3 breast cancer (>5 cm): real-world evidence from the Chinese Society of Clinical Oncology Breast Cancer database
Translational Breast Cancer Research
2020;
1:
16
(30 July 2020)
Original Article
Analysis of the treatment patterns and safety of early breast cancer patients during the COVID-19 pandemic
Translational Breast Cancer Research
2020;
1:
15
(30 July 2020)
Original Article
Breast cancer patients with low estrogen receptor expression gain no significant survival benefit from endocrine therapy: a real-world study from China
Translational Breast Cancer Research
2020;
1:
14
(30 July 2020)
Original Article
Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study
Translational Breast Cancer Research
2020;
1:
13
(30 July 2020)
Editorial
How to optimize real-world study: concept, opportunities, and evidence quality
Translational Breast Cancer Research
2020;
1:
12
(30 July 2020)
Editorial
Pyrotinib: a new promising targeted agent for human epidermal growth factor receptor 2-positive breast cancer
Translational Breast Cancer Research
2020;
1:
11
(30 July 2020)
Editorial
The counterattack of anti-HER2 small molecule compounds has started
Translational Breast Cancer Research
2020;
1:
10
(30 July 2020)
